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Abstract
Target population This recommendation applies to adults
with newly diagnosed brain metastases; however, the rec-
ommendation below does not apply to the exquisitely
chemosensitive tumors, such as germinomas metastatic to
the brain.
Recommendation Should patients with brain metasta-
ses receive chemotherapy in addition to whole brain
radiotherapy (WBRT)?
Level 1 Routine use of chemotherapy following WBRT for
brain metastases has not been shown to increase survival
and is not recommended. Four class I studies examined the
role of carboplatin, chloroethylnitrosoureas, tegafur and
temozolomide, and all resulted in no survival beneﬁt. Two
caveats are provided in order to allow the treating physi-
cian to individualize decision-making: First, the majority
of the data are limited to non small cell lung (NSCLC) and
breast cancer; therefore, in other tumor histologies, the
possibility of clinical beneﬁt cannot be absolutely ruled
out. Second, the addition of chemotherapy to WBRT
improved response rates in some, but not all trials; response
rate was not the primary endpoint in most of these trials
and end-point assessment was non-centralized, non-blin-
ded, and post-hoc. Enrollment in chemotherapy-related
clinical trials is encouraged.
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Rationale
Brain metastases are a common complication of systemic
cancer, occurring in 20–40% of patients [1]. The primary
therapeutic approach for disseminated systemic disease
remains chemotherapy, and therefore, one might expect
this to be a logical choice for brain metastases as well.
However, several issues have limited the application of
chemotherapy in this context. One concern involves the
ability of chemotherapeutic agents to cross the blood–brain
barrier (BBB). Many chemotherapeutic agents are rela-
tively excluded from the brain, and ones that do penetrate,
may do so in insufﬁcient concentrations. Although there is
relative breakdown of the BBB in and around a metastatic
lesion in the brain, some studies have demonstrated that
there is still only very limited drug concentration within the
lesion. Recent ﬁndings suggest that efﬂux pumps may play
a major role in this phenomenon [2]. Some animal studies
have shown that if metastatic tumors enhance strongly on
computed tomography (CT) or magnetic resonance imag-
ing (MRI), that the blood–brain barrier (BBB) is sufﬁ-
ciently impaired to allow entry of chemotherapeutic drugs.
Newer agents which cross the BBB have and are being
developed as well. New molecular based therapies directed
against growth factor receptors and other protein kinases
are being investigated, however their large size also raises
concerns about penetrability. There is also the long-
standing observation that intracranial response rates to
chemotherapy are typically lower than in the extracranial
compartment, and a common hypothesis for this ﬁnding is
that patients are pre-exposed to cytotoxic therapies, and it
is the chemoresistant clones that metastasize to the brain.
However, data in newly diagnosed, previously untreated
patients with small cell lung cancer (SCLC) suggest that
intracranial response rates remain signiﬁcantly lower than
extracranial response rates, thereby suggesting that
chemoresistant clones alone do not necessarily explain this
dichotomy [3]. Some types of metastatic brain tumors may
respond to chemotherapy to some degree, including breast
cancer, germ cell cancer, and ovarian cancer in addition to
SCLC.
The use of chemotherapy for brain metastases has been
explored in four primary contexts:
1. WBRT vs. WBRT plus chemotherapy
2. Chemotherapy vs. chemotherapy plus WBRT
3. Chemotherapy plus concurrent WBRT vs. chemother-
apy plus delayed WBRT
4. Chemotherapy ﬁrst, followed by WBRT vs. WBRT
ﬁrst, followed by chemotherapy
Methods
To answer the above question and its subparts, a compre-
hensive systematic literature review was performed.
Search strategy
The following electronic databases were searched from
1990 to September 2008: MEDLINE
 , Embase
 , Coch-
rane Database of Systematic Reviews, Cochrane Con-
trolled Trials Registry, and Cochrane Database of
Abstracts of Reviews of Effects. A broad search strategy
using a combination of subheadings and text words was
employed. The search strategy is documented in the
methodology paper for this guideline series by Robinson
et al. [4] Reference lists of included studies were also
reviewed.
For inclusion in this analysis, the following criteria had
to be met:
• Published in English with a publication date of 1990
forward.
• Patients with newly diagnosed brain metastases.
• Fully published peer-reviewed primary comparative
studies (all comparative study designs for primary data
collection included; e.g., RCT, non-randomized trials,
cohort studies or case–control studies).
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123• Any comparative studies evaluating chemotherapy
alone or in combination with other treatment modalities
for the treatment of newly diagnosed brain metastases.
• Number of study participants with newly diagnosed
brain metastases C5 per study arm for at least two of
the study arms.
• Baseline information on study participants is provided
by treatment group in studies evaluating interventions
exclusively in patients with newly diagnosed brain
metastases. For studies with mixed populations (i.e.,
includes participants with conditions other than newly
diagnosed brain metastases), baseline information is
provided for the intervention sub-groups of participants
with newly diagnosed brain metastases.
Study selection and quality assessment
Two independent reviewers evaluated citations using
a priori criteria for relevance and documented decisions in
standardized forms. Cases of disagreement were resolved
by a third reviewer. The same methodology was used for
full text screening of potentially relevant papers. Studies
which met the eligibility criteria were data extracted by one
reviewer and the extracted information was checked by a
second reviewer. The PEDro scale [5, 6] was used to rate
the quality of randomized trials. The quality of compara-
tive studies using non-randomized designs was evaluated
using eight items selected and modiﬁed from existing
scales.
Evidence classiﬁcation and recommendation levels
Both the quality of the evidence and the strength of the
recommendations were graded according to the American
Association of Neurological Surgeons (AANS)/Congress
of Neurological Surgeons (CNS) criteria. These criteria are
provided in the methodology paper for this guideline series.
Guideline development process
The AANS/CNS convened a multi-disciplinary panel of
clinical experts to develop a series of practice guidelines on
the management of brain metastases based on a systematic
review of the literature conducted in collaboration with
methodologists at the McMaster University Evidence-
based Practice Center.
Scientiﬁc foundation
The literature search resulted in the identiﬁcation of 16,966
citations of which 16,936 were eliminated at abstract
review as not having relevance to the speciﬁc question. The
remaining 30 studies were subject to full text screening,
and 20 were excluded, seven because they lacked baseline
patient data by treatment group, 10 because they lacked
baseline patient subset data by treatment group, two
because there was no treatment comparison of interest, and
one because it was not a comparative study. Ten eligible
studies [7–16] were therefore fully reviewed and form the
basis of this report (see Table 1; Fig. 1).
These 10 studies were assigned to the four sub-questions
above as follows:
WBRT vs. WBRT ? chemotherapy: 5 studies [7–11].
Chemotherapy vs. chemotherapy ? WBRT: 3 studies
[12, 13, 17].
Chemotherapy ? concurrent WBRT vs. chemother-
apy ? delayed WBRT: 1 study [15].
Chemotherapy ﬁrst, followed by WBRT vs. WBRT ﬁrst,
followed by chemotherapy: 1 study [16].
Clearly, the role of chemotherapy in the management of
brain metastases has been explored in a very limited number
of controlled comparative trials, and therefore the class of
evidence and hence the level of recommendations have
limited applicability. In addition, outcome parameters vary
between the studies, further complicating direct compari-
sons; nonetheless, these studies do provide important
information regarding the endpoints of survival, tumor
response to therapy, and time to progression for speciﬁc
clinical scenarios. Further, we must also acknowledge that
these recommendations do not apply to the exquisitely
chemosensitive tumors, such as germinomas metastatic to
the brain. Finally, although many targeted agents hold some
promise in the management of metastatic disease to the
brain, controlled comparative trials are just beginning to be
conducted, and the data are not sufﬁciently mature to be
included in this analysis. Refer to Table 1 for details of the
included studies.
WBRT vs. WBRT plus chemotherapy
Five studies [7–11] met the inclusion criteria for this sub-
question. Four of ﬁve studies provide class I evidence (two
are phase III randomized trials, and two are randomized
phase II trials) and the ﬁfth is a retrospective cohort study,
providing, at best, class II evidence.
In 2004 Guerrieri et al. [7] published a multi-institu-
tional, randomized controlled trial (RCT) of palliative
radiation with concomitant carboplatin for patients with
brain metastases from NSCLC, with overall survival as the
primary endpoint. Patients with histologically or cytologi-
cally proven NSCLC, with C1 brain metastases identiﬁed
by CT or MRI, deemed either inoperable or who refused
J Neurooncol (2010) 96:71–83 73
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123surgery, with a WHO performance status of 0, 1 or 2, and
who had adequate laboratory parameters were included.
Prior chemotherapy or brain radiotherapy were exclusion
criteria. Patients were stratiﬁed by institution. Forty-two
patients were randomized to two groups, G1: WBRT
(n = 21) G2: WBRT ? Carboplatin (n = 21). The radio-
therapy dose was 20 Gy in 5 fractions in both arms and the
Carboplatin dose was 70 mg/m
2 IV/day 9 5 days. The
detailed demographic breakdown is presented in the tabular
summary.Patientswerewell-balancedbetweenthetwoarms
by age, gender, histology, and number of brain lesions; the
status of extra-cranial disease was not reported. There was a
mismatch in terms of WHO performance status between the
two groups; there were 33% vs. 67% PS 1 patients in G1 vs.
G2, and 52% vs. 19% PS 2 patients in G1 vs. G2. Addi-
tionally, in G1, 24% of patients had a neurologic function
statusof3,comparedto5%inG2.Medianfollow-upwasnot
reported. The degree of steroid usage in each of the two
groups was not reported. The trial was terminated early due
to low patient accrual, thus limiting the ability to draw sta-
tistically signiﬁcant conclusions.
The median survival was comparable, 4.4 vs. 3.7 months
for G1 vs. G2, which was statistically not signiﬁcant.
Overall response was reported in a subset of patients. Of 11
assessed patients in G1, the OR was 10%, compared to 29%
in 16 patients in G2, which was statistically not signiﬁcantly
different; however, when patients were compared in terms
of WHO performance status compared to pre-treatment,
14% in G1 were worse, and 57% in G2 were worse; simi-
larly, in terms of neurological function status compared to
pre-treatment, 10% were worse in G1, compared to 38% in
G2. Although WHO performance and neurologic function
deterioration were more common in G2, there were no
signiﬁcant differences in gastrointestinal or hematological
toxicities between the groups.
This trial, with incomplete accrual, failed to meet the
primary objective of demonstrating improved survival with
the addition of carboplatin to WBRT in NSCLC patients
with brain metastases. While designed as a class I study,
the aforementioned concerns regarding this trial may fur-
ther limit its impact when making treatment recommen-
dations, as no statistically signiﬁcant differences in survival
were noted between the groups. However, the study does
appear to support the use of chemotherapy when secondary
endpoints such as response rate are analyzed.
The second major RCT, also designed as a class I study,
was reported by Ushio et al. [8] in 1991. Patients with a
diagnosis of brain metastases from lung cancer with the
primary lesion and/or systemic lesions relatively well
controlled, and a projected survival of [4 months, were
enrolled. Previous chemotherapy with any of the drugs
used in this study was an exclusion factor. Patients were
randomized to three groups: G1: WBRT alone (n = 25),
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123G2: WBRT ? Chloroethylnitrosoureas (either methyl-
CCNU or ACNU) (n = 34), G3: WBRT ? Tega-
fur ? Chloroethylnitrosoureas (n = 29). In all three
groups, surgery was permitted prior to WBRT, if the
lesions could be removed without neurologic deﬁcits. The
WBRT dose was 40 Gy in 1.5–2 Gy fractions; the methyl-
CCNU dose was 100–120 mg/m
2 orally every 6–8 weeks
(at midpoint in the study, methyl-CCNU became unavail-
able and was replaced with ACNU 80–100 mg/m
2 IV
every 6–8 weeks) and the Tegafur dose was 300 mg/m
2/
day given orally. Patients were well balanced in all three
groups by gender, age, histology, and number of brain
metastases. The status of extra-cranial disease, the degree
of corticosteroid use, and baseline functional performance
score was not reported, and median follow-up of patients
was not available.
The primary endpoint was tumor control, but median
survival was also analyzed. There was no statistically
signiﬁcant difference in survival between the three arms
(27, 29, and 30.5 weeks for G1, G2 and G3 respectively).
Intracranial response analysis revealed an overall response
rate of 36, 69, and 74% for groups 1–3, respectively. When
the response rate for group 1 was statistically compared to
that of group 3, it reached statistical signiﬁcance, with a
P\0.05 (overall response rate: 36 vs. 74%; the compa-
rable complete response rates for the two groups were four
of 14 patients vs. 12 of 19 patients). Functional perfor-
mance outcome was not reported nor was the time to
intracranial recurrence/progression. The causes of death
were ascertained, and the rate of neurologic death was 3/25
in G1, 0/32 in G2 and 4/28 in G3. Adverse events were not
reported in detail in the study; however two patients were
thought to have died from the effects of chemotherapy (one
from pancytopenia and one from cardiac failure).
In summary, this RCT of 88 patients did not show a
survival improvement with the addition of chemotherapy,
but showed a statistically signiﬁcant improvement in
response rates, especially the rates of complete response,
with the addition of Tegafur and a nitrosourea to WBRT in
patients with NSCLC.
In 2002, Antonadou et al. [9] reported on a phase II RCT
in which patients with brain metastases were randomized to
WBRT alone or WBRT plus temozolomide. Adult patients
aged 18 or older, with brain metastases from histologically
Title and Abstract Screening 
n=16,966
Full Text Screening 
n=30
Excluded at Title and 
Abstract
n=16,936
Eligible Studies 
n=10
20 Excluded 
No baseline patient data by treatment group  …………………….7 
No baseline patient data by brain metastases sub-group ………..10 
No treatment comparison of interest  .............................................2
Non-comparative study  ………………………………………….1 
10 Included 
WBRT vs. WBRT + chemotherapy………………………………………….5 
Chemotherapy vs. chemotherapy + WBRT………………………………….3 
WBRT + concurrent chemotherapy vs. WBRT + delayed chemotherapy…...1 
Upfront chemotherapy + WBRT vs. upfront WBRT + chemotherapy............1 
Fig. 1 Flow of studies to ﬁnal
number of eligible studies
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123proven cancer of the lung, breast, or unknown primary,
with a performance status B2, life expectancy C3 months,
and adequate hematologic, renal, hepatic function, were
included. Exclusion factors were previous chemotherapy or
radiotherapy for brain metastases, or any uncontrollable,
life-threatening systemic disease, or pregnant or lactating
women. Patients (n = 23) in group 1 received 40 Gy of
WBRT in 20 fractions of 2 Gy each. In group 2, (n = 25)
patients received the same dose of WBRT with 75 mg/m
2/
day of temozolomide orally during WBRT and continued
temozolomide therapy (200 mg/m
2/day for 5 days every
28 days for an additional 6 cycles after WBRT. The
median follow-up time was 4 months. The groups were
well-balanced with respect to gender, age, baseline per-
formance status, neurologic functional level, and tumor
type, with 65% of patients having NSCLC, as well as
number of brain metastases and presence of extracranial
disease.
The primary study endpoints were radiologic response
and neurologic symptom evaluation. Survival was also
analyzed. The median survival was 7 vs. 8.6 months for G1
vs. G2 (not statistically signiﬁcant). The overall response
rate was 67% vs. 96% for G1 vs.G2, with a P = 0.017
which was statistically signiﬁcant. The time to recurrence
or progression of disease in the brain, and also the cause of
death were not reported. There was neurologic improve-
ment in the group receiving temozolomide, and fewer
patients required corticosteroids after treatment in the
temozolomide group compared with radiotherapy alone.
The temozolomide was generally well tolerated with some
toxicities statistically more common in that group,
including nausea, and vomiting. Hematologic toxicity was
reversible.
In summary, this RCT of 48 patients did not show a
survival improvement with the addition of temozolomide
chemotherapy, but showed a statistically signiﬁcant
improvement in response rates and an improvement in
neurologic function with the addition of temozolomide to
WBRT, which constitutes class I evidence. We are aware
of a subsequent larger randomized trial performed by the
same group, but this has never been published in manu-
script form and is therefore not available as a peer-
reviewed literature item.
In 2003, Verger et al. [10] reported on a phase II RCT in
patients with brain metastases randomized to WBRT alone
or WBRT plus temozolomide. Adult patients aged 18 or
older, with brain metastases from histologically proven
cancer, unsuitable for surgery or SRS, with a Karnofsky
performance score (KPS) C50, and adequate hematologic,
renal, and hepatic function, were included. Exclusion fac-
tors included previous chemotherapy within the previous
3 weeks, prior cranial radiotherapy, leptomeningeal
involvement, intratumoral hemorrhage, and clinical or
psychiatric conditions that would interfere with completion
or required evaluations.
Stratiﬁcation variables included age, KPS and type of
primary tumor. Patients (n = 41) in G1 received 30 Gy
WBRT in 10 fractions of 3 Gy. In G2, 41 patients received
the same dose of WBRT with 75 mg/m
2/day of temozol-
omide orally during WBRT and continued temozolomide
therapy (150–200 mg/m
2/day for 5 days every 28 days for
an additional 2 cycles after WBRT.) The median follow-up
time was not reported. The groups were well-balanced with
respect to gender, age, baseline performance status, tumor
type (with 53 and 49% of patients having NSCLC), number
of brain metastases and presence of extracranial disease.
Unlike in the other studies mentioned above, the primary
outcome in this trial was an analysis of neurologic toxicity.
Radiologic response and progression free survival were also
analyzed secondarily. The trial was stopped prematurely
due to low patient accrual. The median survival was 3.1 vs.
4.5 months for G1 vs. G2 and was not statistically signiﬁ-
cant. The overall response at day 30 was 32% for both G1
and G2. At 90 days, the radiologic response could only be
assessed in 35 patients and was similar in the two groups.
Freedom from intracranial progression at 90 days was 54
vs. 72% (P = 0.03) in favor of the WBRT plus temozolo-
mide group. Functional performance change was not
reported. There was a statistically signiﬁcant difference in
cause of death between the two groups, with neurologic
death occurring in 69% in G1 compared to 41% in G2
(P = 0.029) again favoring the WBRT plus temozolomide
group.Noacuteneurologic toxicitydeveloped intheWBRT
plus temozolomide arm and temozolomide did not interfere
with delivery of WBRT.
In summary, this prematurely terminated RCT of 82
patients, which was designed as a class I study, did not
show either a survival improvement with the addition of
temozolomide chemotherapy, or statistically signiﬁcant
improvement in response rates, with the addition of tem-
ozolomide to WBRT. Although insufﬁcient to support a
level 1 recommendation, the evidence in this study did
show an improvement with the addition of chemotherapy
in the secondary endpoints of intracranial progression and
neurologic death.
Finally, in 2005, Kim et al. [11] published a retrospec-
tive cohort study which included NSCLC patients with
synchronous brain metastases who received WBRT for
intracranial lesions found during evaluation of neurologic
symptoms. The exclusion criteria were patients who did not
receive WBRT, leptomeningeal carcinomatosis, Eastern
Cooperative Oncology Group (ECOG) performance status
of grade 3 or 4, surgical resection or radiotherapy for
thoracic lesions, or open surgical removal of intracranial
metastatic lesions. The interventions included G1: WBRT
(n = 32) and G2: WBRT ? platinum-based chemotherapy
78 J Neurooncol (2010) 96:71–83
123(n = 31). The WBRT dose was 30 to 40 Gy, and several
platinum doublets were employed.
The median follow-up was not reported. The groups
were well balanced in terms of gender, age, tumor type
(100% NSCLC), number of brain metastases, presence of
extracranial disease, and baseline performance score. The
primary outcome was not speciﬁed, but there was a marked
difference in median survival, G1: 19.0 weeks vs. G2:
58.1 weeks (P\0.001). No data were presented regarding
tumor control, time to intracranial recurrence, or cause of
death. The neurologic response was not signiﬁcantly dif-
ferent between the two groups.
In summary, this non-randomized cohort study of 63
patients showed a survival improvement with the addition
of various platinum-based doublet chemotherapies in
addition to WBRT. This constitutes class II evidence.
There was no improvement in secondary endpoints.
Chemotherapy vs. chemotherapy plus WBRT
In2003,Mornexetal.[12]publishedresultsofaprospective
randomized phase III trial of fotemustine plus WBRT
(n = 37) versus fotemustine alone (n = 39) in patients with
cerebral metastases from malignant melanoma. The main
objectives were objective response and time to cerebral
progression. Patients with histologically conﬁrmed malig-
nant melanoma with at least one non-resectable metastasis
and who ﬁt other parameters were included. Patients were
required to have received no chemotherapy in the prior
4 weeks, no previous nitrosourea-based chemotherapy and
no previous cerebral radiotherapy. Both arms were well
balanced with respect to the number of cerebral metastases,
extentofvisceraldiseaseandage.Patientsinthefotemustine
alone arm had worse baseline performance status (ECOG 2–
3 54% compared to 30% in the fotemustine plus WBRT
group) and had been treated with more chemoimmunother-
apy (59 versus 32% respectively). Additionally, the median
time interval between the primary diagnosis and the onset of
brain metastases was different between the two groups
(550 daysforthefotemustinealonegroupand1131 daysfor
the fotemustine ? WBRT group). The dose of WBRT was
37.5 Gy in 15 fractions over 3 weeks. Fotemustine was
given intravenously at 100 mg/m
2 on days 1, 8 and 15, fol-
lowedbya5 weekrestperiodandthenevery3 weeksinnon-
progressing patients. Although the fotemustine alone
patients had worse prognostic factors, there was no differ-
ence in cerebral response or control or in overall survival
(86 days in the fotemustine group vs. 105 days in the com-
bined treatment group). There was a statistically signiﬁcant
difference in time to cerebral progression favoring the
WBRT ? fotemustine group (P = 0.028) with that group
having a median time to objective cerebral progression of
56 days compared to 49 days in the chemotherapy alone
group. This constitutes class I evidence.
A phase III randomized study comparing teniposide (G1)
versus teniposide with WBRT (G2) in patients with brain
metastasesfromSCLCwasreportedbyPostmusetal.[13]in
2000. Their stated goal was to evaluate the role of WBRT in
SCLC patients with brain metastases. The primary end point
was survival. Teniposide was administered intravenously at
120 mg/m
2 on days 1, 3, and 5 every 3 weeks up to a max-
imum of12coursesoruntildisease progressioneither inside
or outside the brain. WBRT, dosed at 30 Gy in 10 fractions
over 2 weeks, hadtobestartedwithin3 weeks ofthe startof
treatment with teniposide. Dexamethasone dosing parame-
terswereoutlined.Ofthe134patientsrandomized,120were
eligible (60 in each group). The groups were well matched
for age, ECOG performance status, neurologic function and
number of brain metastases. Although the response rate in
the combined modality group (G2) was signiﬁcantly higher
(57%)thanintheteniposidealonegroup(G1)(22%),thisdid
not result in a prolongation of overall survival, thought to be
duetoprogressionofdiseaseoutsidethebrain(3.2 monthsin
G1 and 3.5 months in G2). Time to progression in the brain
was assessed by CT scan rather than MRI in this European
study and was signiﬁcantly longer in the combined modality
group. This RCT constitutes class I evidence.
In a retrospective cohort study, Moscetti et al. [14]
analyzed 110 patients (G1) with newly diagnosed NSCLC
with brain metastases who had received up-front platinum-
based chemotherapy and 46 patients who had received
WBRT followed by chemotherapy (G2). The authors
sought to analyze the process by which six oncologic
centers guided the pattern of care. In this survey of unse-
lected patients, choice of treatment appeared guided by
presence of neurologic symptoms from the brain metasta-
ses. The response rate in the brain was 27.3% in G1 and
34.8% in G2 with no signiﬁcant difference in median time
to progression in the brain (6 months in both groups). With
regard to the ﬁrst treatment option, the median survival was
10 months for G1 and 14 months for G2. While this study
does show that some patients with brain metastases from
NSCLC will respond initially to platinum-based chemo-
therapy, there are too many variables in the patient cohorts
and reasons for treatment choice to derive any meaningful
data for recommendation. This retrospective study consti-
tutes class II evidence.
Chemotherapy with concomitant WBRT vs.
chemotherapy with delayed WBRT
Robinet et al. [15] published a randomized trial in 1998
evaluating the use of systemic chemotherapy for the
treatment of inoperable brain metastases from NSCLC with
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They treated 85 patients with cisplatin and vinorelbine used
concurrently with WBRT and 86 treated with the same
chemotherapy, but with WBRT delayed for at least 2
cycles. No WBRT-alone group was included. Patients had
histologically veriﬁed NSCLC and at least one brain
metastasis[10 mm in diameter. Patients had an acceptable
performance status and good end-organ function. Patients
were treated with cisplatin 100 mg/m
2 on day 1, vinorel-
bine 30 mg/m
2 on days 1, 8, 15 and 22, with cycles repe-
ated every 4 weeks. In one group, chemotherapy was
started concurrent with WBRT, administered as 30 Gy in
10 fractions of 3 Gy given over 2 weeks. In the other
group, radiation was deferred.
Median follow-up was not reported, but 171 patients
were accrued and the two treatment groups were balanced
with regard to age, sex, tumor type and single vs. multiple
brain metastases. Extracranial disease and baseline per-
formance status were also balanced between the treatment
groups. The primary outcome reported was overall sur-
vival. There was no signiﬁcant difference between the
groups with regard to overall survival. The secondary
outcome of overall response was also similar at approxi-
mately 20% in both groups. This was a combined assess-
ment of brain and extracranial disease response. Functional
performance was not reported. Neurologic cause of death
was reported as 88% in the group with delayed WBRT as
opposed to 81% in the group treated with concurrent
WBRT and chemotherapy. Adverse events included toxic
deaths in both groups in approximately 8%, and similar
instances of myelosuppression, neuro- and renal toxicity
and infection. These were equally distributed in both
groups.
As a randomized trial of 171 patients, this study pro-
vides class I evidence for the similarity in outcome in the
treatment of brain metastases from NSCLC with chemo-
therapy with concurrent vs. delayed WBRT. The initial
response rates reported are similar with chemotherapy with
or without concurrent WBRT, but overall survival is not
signiﬁcantly different. This study does not address the role
of concurrent vs. delayed chemotherapy, but rather con-
current vs. delayed WBRT with chemotherapy, and
remains the one and only study to have attempted to answer
the question, without any conﬁrmatory trials.
Chemotherapy ﬁrst followed by WBRT vs.
WBRT ﬁrst followed by Chemotherapy
Lee et al. [16] published a randomized trial in 2008
testing the use of systemic chemotherapy ﬁrst followed by
WBRT vs. WBRT ﬁrst followed by systemic chemo-
therapy for the treatment of advanced NSCLC with
synchronous brain metastases. They treated 25 patients
with gemicitabine and vinorelbine (up to 6 cycles) used
prior to WBRT and 23 treated with upfront WBRT fol-
lowed by the same chemotherapy. No WBRT-alone group
was included. Patients had histologically veriﬁed NSCLC
and clinically silent brain metastasis, not amenable to
resection. Patients were 18–75 years of age, with an
ECOG performance status of 0–2, measurable disease in
both intracranial and extracranial sites, and adequate
renal, hepatic and marrow function. The dose of gemcit-
abine was 900 mg/m
2 on day 1, and vinorelbine was
25 mg/m
2 on days 1 and 8, every 3 weeks, with a max-
imum of 6 cycles or disease progression. WBRT was
administered as 30 Gy in 10 fractions of 3 Gy given over
2 weeks. In the WBRT-ﬁrst arm, chemotherapy was ini-
tiated after at least a 2 week rest period.
In the primary chemotherapy arm, all patients received
WBRT after systemic disease progression or 6 cycles, and
no patient had progressive neurologic symptoms or signs
by the time WBRT was started. In the WBRT-ﬁrst arm,
four patients deteriorated or died prior to receiving che-
motherapy. There was no difference in overall response
rates between the two arms (39 vs. 28%, WBRT ﬁrst vs.
chemo ﬁrst); intracranial response was closely related to
extracranial response (k = 0.82). With a median follow-
up of 40 months, there was no difference in progression-
free survival (PFS) or overall survival. Of note, this study
was conducted in Korea, and the proportion of adeno-
carcinoma histology was 23/25 in the primary chemo-
therapy arm, and 17/23 in the WBRT ﬁrst arm. Quality of
life (QOL) parameters were evaluated in 33 patients using
the European Organisation for Research and Treatment of
Cancer (EORTC) questionnaires C30 and L13. Global
health status was signiﬁcantly impaired at baseline, but
equally so in both arms. After WBRT, global health
status was found to be signiﬁcantly impaired, with a
decreased mean score of 48 from 65. In the chemother-
apy-ﬁrst arm, cognitive function became more impaired
as chemotherapy proceeded, whereas in the WBRT-ﬁrst
arm, cognitive function declined for a short period after
WBRT, but improved slightly, thereafter. Grade 3 or 4
neutropenia occurred more frequently in the WBRT-ﬁrst
arm (79 vs. 40%, P = 0.014). Other toxicities were
comparable.
As a randomized trial of 48 patients, this study provides
class I evidence for the similarity in outcome in the treat-
ment of brain metastases from NSCLC with either che-
motherapy with delayed WBRT or WBRT followed by
chemotherapy, with the caveat that all patients were
asymptomatic at study entry, and patient ethnicity may also
need to be factored in, given the known variability in
clinical behavior and response between Caucasian and Far-
Eastern patients.
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The role of chemotherapy in the management of brain
metastases has been explored in a very limited number of
controlled comparative trials, and therefore the class of
evidence and hence the level of recommendations have
limited applicability. Further, it has tobe acknowledged that
these recommendations do not apply to the exquisitely che-
mosensitive tumors, such as germinomas metastatic to the
brain. Additionally, these studies have been conducted
mostly in patients with NSCLC and extrapolating to other
histologictypeswouldbeconsideredinadequatelysupported
by the data. Further confounding the conclusions is the rec-
ognition that some of these patients were pre-treated with
chemotherapy, whereas others were chemotherapy-naive,
and the differences in outcomes might reﬂect prior exposure
tosystemictherapy,whichhasessentiallybeeninadequately
accounted for in most of these trials. Primary endpoints also
variedbetweenthetrials,withsomestudiesunabletoreacha
statistically signiﬁcant conclusion with regard to a primary
endpoint,suchasoverallsurvival,whilereportingsigniﬁcant
differences in other secondary endpoints, such as tumor
responserates.Thevariabilityintheseendpointscontributes
tothedifﬁcultyinmakingdeﬁnitivetreatmentdecisions,but
the caveats are presented so that clinicians can make
informed,individualizedclinicaldecisionsfortheirpatients.
Lastly, the inclusion in some trials of only asymptomatic
patients also warrants consideration, because results from
such trials cannot be extrapolated to symptomatic patients.
Major conclusions that emerge from these studies
include:
1. The lack of clear and robust survival beneﬁt with the
addition of chemotherapy to WBRT.
2. Enhanced response rates, speciﬁcally in NSCLC with
the addition of chemotherapy to WBRT.
3. In terms of secondary endpoints such as time to
neurologic progression, steroid dose, etc., the data and
results are mixed and do not permit robust conclusions.
4. In at least one trial, time to progression was improved
by the addition of WBRT to chemotherapy as
compared to chemotherapy alone; however, the evi-
dence to corroborate this study is sparse.
5. A single trial provides evidence that outcome is similar
whether WBRT is delivered upfront with chemother-
apy or delayed by up to 2 cycles, but the data remains
too limited to support deﬁnitive recommendations for
the delay of radiation therapy, especially given the lack
of any known survival advantage with chemotherapy.
6. Similarly, the sequencing question (does it matter if
chemotherapy precedes WBRT or vice versa?) has
been inadequately addressed and the data are too
sparse to make deﬁnitive conclusions.
Key issues for future investigation
Although many targeted agents hold some promise in the
management of metastatic disease to the brain, controlled
comparative trials are just beginning to be conducted, and
the data are not sufﬁciently mature to be included in this
analysis. This remains a major future area of investigation.
Neurocognitive function remains poorly addressed in
the majority of these trials and clearly should be accounted
for in future trials.
The following is a list of major ongoing or recently
closed randomized trials pertaining to the use of chemo-
therapy that evaluate treatment comparisons addressed by
this guideline paper for the management of newly diag-
nosed brain metastases:
1. Temozolomide for Treatment of Brain Metastases
From Non-Small Cell Lung Cancer (Study P03247AM3)
(COMPLETED)
Ofﬁcial title A Randomized, Open-Label Phase 2 Study
of Temozolomide Added to Whole Brain Radiation Ther-
apy Versus Whole Brain Radiation Therapy Alone for the
Treatment of Brain Metastasis From Non-Small Cell Lung
Cancer
Status Completed
Clinicaltrials.gov Identiﬁer NCT00076856
Principal Investigator Not provided
Location Not provided
Sponsors and Collaborators Schering-Plough
2. Study of Temozolomide in the Treatment of Brain
Metastasis From Non-Small-Cell Lung Cancer (Study
P02143) (COMPLETED)
Ofﬁcial title A Phase II Study of Temozolomide (SCH
52365) in Subjects With Brain Metastasis From Non-
Small-Cell Lung Cancer
Status Completed
Clinicaltrials.gov Identiﬁer NCT00034697
Principal Investigator Not provided
Location Not provided
Sponsors and Collaborators Schering-Plough
3. Safety and Tolerability of Low-Dose Temozolomide
During Whole Brain Radiation in Patients With Cerebral
Metastases From Non-Small-Cell Lung Cancer (Study
P04071) (TERMINATED)
Ofﬁcial title Randomized Phase II Study: Temozolo-
mide (TMZ) Concomitant to Radiotherapy Followed by
Sequential TMZ in Advanced NSCLC Patients With CNS
Metastasis Versus Radiotherapy Alone
Status Terminated (Phase II)
Clinicaltrials.gov Identiﬁer NCT00266812
Principal Investigator Not provided
Location Not provided
Sponsors and Collaborators
Schering-Plough
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4. Radiation Therapy With or Without Temozolomide in
Treating Patients With Non-Small Cell Lung Cancer That
is Metastatic to the Brain
Ofﬁcial title A Phase II Study Of Temozolomide (SCH
52365) In Subjects With Brain Metastasis From Nonsmall
Cell Lung Cancer
Status Active, not recruiting (Phase II)
Clinicaltrials.gov Identiﬁer NCT00030836
Principal Investigator Lauren E. Abrey, MD, Memorial
Sloan-Kettering Cancer Center
Location United States
Sponsors and Collaborators
Memorial Sloan-Kettering Cancer Center
National Cancer Institute (NCI)
5. Temozolomide With or Without Radiation Therapy to
the Brain in Treating Patients With Stage IV Melanoma
That Is Metastatic to the Brain
Ofﬁcial title Temozolomide Versus Temozolo-
mide ? Whole Brain Radiation In Stage IV Melanoma
Patients With Asymptomatic Brain Metastases
Status Active, not recruiting (Phase III)
Clinicaltrials.gov Identiﬁer NCT00020839
Principal Investigator Juergen C. Becker, MD, PhD
Universitaets-Hautklinik Wuerzburg
Location Europe (33 locations)
Sponsors and Collaborators
European Organization for Research and Treatment of
Cancer
6. Radiation Therapy Combined With Either Geﬁtinib or
Temozolomide in Treating Patients With Non-Small Cell
Lung Cancer and Brain Metastases
Ofﬁcial title Whole Brain Radiotherapy in Combination
With Geﬁtinib (Iressa) or Temozolomide (Temodal) for
Brain Metastases From Non-Small Lung Cancer (NSCLC)
A Randomized Phase II Trial
Status Recruiting (Phase II)
Clinicaltrials.gov Identiﬁer NCT00238251
Principal Investigators
Study Chair: Gianfranco Pesce, MD Oncology Institute
of Southern Switzerland
Investigator: Roger Stupp, MD Centre Hospitalier Uni-
versitaire Vaudois
Location Switzerland
Sponsors and Collaborators Swiss Group for Clinical
Cancer Research
7. Radiation Therapy and Stereotactic Radiosurgery
With or Without Temozolomide or Erlotinib in Treating
Patients With Brain Metastases Secondary to Non-Small
Cell Lung Cancer
Ofﬁcial title A Phase III Trial Comparing Whole Brain
Radiation And Stereotactic Radiosurgery Alone Versus
With Temozolomide Or Erlotinib In Patients With Non-
Small Cell Lung Cancer And 1-3 Brain Metastases
Status Recruiting (Phase III)
Clinicaltrials.gov Identiﬁer NCT00096265
Principal Investigators
Paul Sperduto, MD, MAPP Park Nicollet Cancer Center
Minesh P. Mehta, MD University of Wisconsin,
Madison
H. I. Robins, MD, PhD University of Wisconsin,
Madison
Location United States and Canada (56 locations)
Sponsors and Collaborators
Radiation Therapy Oncology Group
National Cancer Institute (NCI)
8. Comparison Study of WBRT and SRS Alone Versus
With Temozolomide or Erlotinib in Patients With Brain
Metastases of NSCLC
Ofﬁcial title A Phase III Trial Comparing Whole Brain
Radiation (WBRT) and Stereotactic Radiosurgery (SRS)
Alone Versus With Temozolomide or Erlotinib in Patients
With Non-Small Cell Lung Cancer and 1-3 Brain
Metastases
Status Recruiting (Phase III)
Clinicaltrials.gov Identiﬁer NCT00268684
Principal Investigator Felix Bokstein, M.D. Tel-Aviv
Sourasky Medical Center
Location Israel
Sponsors and Collaborators
Tel-Aviv Sourasky Medical Center
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